ANGLE (OTCMKTS:ANPCY – Get Free Report) and Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Profitability
This table compares ANGLE and Maravai LifeSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ANGLE | N/A | N/A | N/A |
| Maravai LifeSciences | -37.07% | -15.70% | -8.17% |
Earnings and Valuation
This table compares ANGLE and Maravai LifeSciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ANGLE | N/A | N/A | N/A | C($0.48) | -0.14 |
| Maravai LifeSciences | $185.74 million | 12.44 | -$130.77 million | ($0.52) | -17.12 |
ANGLE has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
50.2% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and price targets for ANGLE and Maravai LifeSciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ANGLE | 0 | 0 | 0 | 0 | 0.00 |
| Maravai LifeSciences | 2 | 0 | 2 | 0 | 2.00 |
Maravai LifeSciences has a consensus price target of $6.25, suggesting a potential downside of 29.78%. Given Maravai LifeSciences’ stronger consensus rating and higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than ANGLE.
Summary
Maravai LifeSciences beats ANGLE on 6 of the 11 factors compared between the two stocks.
About ANGLE
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
Receive News & Ratings for ANGLE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANGLE and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}